DailyIQ
Last updatedjust now

VRTX·Vertex Pharmaceuticals Incorporated

$485.39
-21.61 (-4.26%)
Overnight$486.20+0.81 (+0.17%)
High
$509.00
Open
$507.55
Market Cap
126.61B
52W High
$560.25
Low
$484.08
P. Close
$485.39
P/E
28.74
52W Low
$395.06
Fwd P/E
24.13
DailyIQ Est.
$599.43
Inst. Ownership
57.0%
Short Interest
1.73%
Days to Cover
4.2
Technical Score (1D)
45
NEUTRAL
News Sentiment
65
BULLISH
On Oct 9, Vertex Pharmaceuticals announced that its drug Alyftrek produced measurable pancreatic function recovery in a subset of pediatric patients during a recent study, a milestone the company highlighted as significant progress toward regulatory approval. The same day, Vertex presented interim data from the ALYFTREK® open‑label extension study at the North American Cystic Fibrosis Conference, showing recovery of exocrine pancreatic function in some children aged 2 to 5 and allowing a few to discontinue pancreatic enzyme replacement therapy. Vertex also reported that its stock closed 1.36% higher on Oct 9, outperforming the broader S&P 500, while analysts noted that the company’s earnings guidance for the November 2 release projects modest year‑over‑year earnings growth of 0.83% and revenue growth of 10.43%. Additionally, a market analysis on Oct 9 noted that Vertex trades at a 29‑times earnings multiple, higher than peers Regeneron and Incyte, and that its operating margin of 37.9% exceeds Incyte’s 31.6%, though its sales growth lagged behind several comparable biotech firms. These developments collectively underscored Vertex’s ongoing pipeline progress and its relative valuation within the biotech sector.
LOW TARGET
$350 -28.0%
1 analysts
MEAN TARGET
$571 +17.5%
21 analysts
HIGH TARGET
$667 +37.2%
15 analysts
PRICE RANGE
$350.00 - $667.00
SB / B / H / S / SS
11/18/6/1/1
DAILYIQ EST.
$599.43 (+23.3%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Country
United States
Website
Symbol
VRTX
Description
Vertex Pharmaceuticals is a biotechnology company focused on the development and commercialization of innovative therapies, with a strong emphasis on treating cystic fibrosis (CF). Its core value proposition lies in providing transformative treatments for CF patients, offering a portfolio of approved medications like TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, which address various patient populations. Beyond CF, Vertex is actively expanding its pipeline with promising candidates for conditions such as sickle cell disease, transfusion-dependent beta thalassemia, acute pain, and APOL1-mediated kidney disease, among others. The company distributes its products through specialty pharmacies and distributors, as well as directly to healthcare providers. Strategic collaborations with other biotech firms further enhance its research and development capabilities.
Bought (1Y)
0 shares
$0
Sold (1Y)
22,469 shares
$10.4M
van Grunsven JasperEVP, CP and NPPO
Award/Grant8,682 shares2026-09-08
Ambrose KristenSVP & Chief Accounting Officer
Award/Grant5,000 shares2026-08-28
SACHS BRUCE I-
Gift6,000 shares2026-08-27
Sachdev AmitEVP Chief Patient & Ext Af Off
Award/Grant8,251 shares2026-07-21
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
Award/Grant8,251 shares2026-07-21
82/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
32.9%
Revenue CAGR
28.2%
Current Ratio
2.90x
Return on Equity
21.2%
Earnings Summary
Vertex Pharmaceuticals is a biotechnology firm specializing in innovative cystic fibrosis (CF) therapies, with a portfolio that includes TRIKAFTA/KAFTRIO, ALYFTREK, SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO, and an expanding pipeline for sickle cell disease, beta thalassemia, and kidney disease. Operating within the healthcare biotechnology sector, Vertex focuses on transformative treatments for rare diseases and leverages specialty pharmacy distribution to reach patients. In the most recent quarters, Q4 2025 revenue fell slightly to $3.19 billion versus an estimate of $3.24 billion, while EPS of $5.03 trailed the $5.17 estimate; Q1 2026 revenue was $2.99 billion against a $3.09 billion estimate and EPS of $4.47 beat the $4.39 estimate, indicating a modest revenue decline but continued earnings strength. Q2 2026 revenue rose to $3.33 billion, surpassing the $3.30 billion estimate, and EPS of $4.73 exceeded the $4.82 estimate, reflecting a rebound in top‑line growth and sustained profitability. Over the past four quarters, Vertex has consistently reported EPS above analyst expectations in three of the last four periods, while revenue growth has been mixed, with a 10.4% increase in Q1 2026 versus Q4 2025 and a 1.3% decline in Q4 2025 versus Q3 2025. Historically, the company has shown a steady YoY revenue trajectory, with a 10% growth in 2025 and a 9% growth in 2026, and has maintained a high operating margin of 37.9%, outperforming peers such as Regeneron and Incyte. Recent news highlights include the positive interim data for ALYFTREK in pediatric CF patients, which could support regulatory approval, and the discontinuation of an mRNA‑based therapy trial with Moderna, signaling a potential pause in that pipeline segment.

EPS

EstBeatMiss
$-0.76$0.91$2.59$4.27$5.94Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$0.01 - -
Q2'26$4.82$4.73-2.0%
Q1'26$4.39$4.47+1.7%
Q4'25$5.17$5.03-2.7%
Q3'25$4.58$4.80+4.9%
Q2'25$4.25$4.52+6.3%

Revenue

EstBeatMiss
$2.9B$3.1B$3.2B$3.4B$3.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$3.5B - -
Q2'26$3.3B$3.3B+1.1%
Q1'26$3.1B$3.0B-3.4%
Q4'25$3.2B$3.2B-1.5%
Q3'25 - $3.1B -
Q2'25 - $3.0B -

Market Data

VRTX Stock Snapshot

NEUTRAL45/100
$486.20+$0.81 (0.2%)
Market cap
126.61B
P/E ratio
28.7
Day range
$484.08 – $509.00
News sentiment
65/100 · Bullish
Analyst target
$571.43 (+17.5%)
Consensus
Buy · 37 analysts
52-week range+23.1% off low · -13.2% from high
$395.06$560.25
Price $486.20 DailyIQ Est. $599.43

The technical read on VRTX is balanced, which usually means the market is waiting on a catalyst. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What VRTX's own history says about today's numbers

Realized volatility (21d)
14.4% 3rd pct
Below its peak
-8.8%
vs 200-day average
+7.4%
Up days (1y)
49%

Vertex Pharmaceuticals Incorporated is currently running 14.4% annualised volatility over the last 21 sessions. Measured against VRTX's own 13 years of daily returns rather than a market-wide average, that is the 3rd percentile — unusually subdued by its own history, against a typical reading of 29.5%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

VRTX is trading -8.8% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -25.1%, and the deepest was -41.7% in 2016. The current pullback is therefore shallower than what this stock gives back in a typical year, which is context worth having before treating it as a dislocation.

Price sits +7.4% from its 200-day moving average. Against every other day in its history, that gap ranks at the 52nd percentile — close to the gap it normally carries. Over the past year VRTX closed higher on 49% of sessions, and it is currently 1 session into a rising streak.

On October specifically: over 13 years of records, VRTX finished the month higher 8 of 13 times, with a median return of +2.5% and an average of -0.3%. Its strongest month historically has been June at +5.2% on average, its weakest September at -2.3%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: VRTX has opened more than 2% away from the prior close in 118 of 3,266 sessions (3.6% of the time), with the largest gaps running +48.0% and -7.1%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, VRTX moved an average of 3.5% in the session after earnings, closing higher 2 of those 3 times, with a median move of +2.6% and a largest of +7.7%.

All figures computed from 3,267 daily closes between 2013-10-14 and 2026-10-09, split-adjusted, recomputed daily. Percentiles are against VRTX's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of VRTX's sector?

Vertex Pharmaceuticals Incorporated sits in the Health Care sector, currently ranked 4th of 12 GICS sectors by relative-strength rotation score (improving). Within its narrower Biotechnology industry group, VRTX ranks 13th of 15 tracked industries, lagging.

Sector rank
#4 of 12
Sector state
Improving
Sector rotation score
73
Industry rank
#13 of 15

Options Market

What is the options market pricing for VRTX?

CallsPuts

For Vertex Pharmaceuticals Incorporated's nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.00), with at-the-money implied volatility around 6.3%. The options market is pricing roughly a ±0.5% move by that expiry — a range of about $493.47–$498.05.

Put/call ratio (2026-10-16)
0.00
ATM implied volatility
6.3%
Total open interest
2
Expected move by 2026-10-16
±0.5% ($493.47–$498.05)

Analyst Rating Changes

Are analysts turning bullish or bearish on VRTX?

RBC Capital most recently reiterated its rating on Vertex Pharmaceuticals Incorporated to Outperform on Oct 8, 2026 with a price target of $576 (from $570). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
RBC Capital — Outperform
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 8, 2026RBC CapitalMaintainedOutperform$570 → $576
Sep 28, 2026UBSMaintainedBuy$585 → $615
Aug 5, 2026Truist SecuritiesMaintainedBuy$560 → $565
Aug 5, 2026BarclaysMaintainedOverweight$615 → $617
Aug 4, 2026TD CowenMaintainedBuy$525 → $550
Aug 4, 2026Cantor FitzgeraldMaintainedOverweight$590 → $595
Aug 4, 2026Canaccord GenuityMaintainedHold$436 → $442
Jul 13, 2026UBSMaintainedBuy$545 → $585
Jul 13, 2026Truist SecuritiesMaintainedBuy$542 → $560
Jul 7, 2026RBC CapitalMaintainedOutperform$543 → $570
Jul 7, 2026BairdMaintainedUnderperform$330 → $350
May 6, 2026BarclaysMaintainedOverweight$607 → $615

Peers & ETF holders

VRTX peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

65/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Vertex Pharmaceuticals closed the day up 1.36%, outperforming the S&P 500’s 0.6% gain. The drugmaker’s shares have slipped 2.2% over the past month, lagging the broader medical sector’s 1.97% decline. Investors are watching the upcoming earnings release on November 2, 2026, where analysts project a modest 0.83% year‑over‑year earnings growth to $4.84 per share and a 10.43% revenue increase to $3.4 billion. The consensus estimates for the full year anticipate earnings of $18.86 per share and revenue of $13.21 billion, marking modest year‑over‑year gains. The market reaction suggests a mild positive bias toward Vertex’s near‑term financial outlook.
What did this article say?
Vertex Pharmaceuticals announced that its drug Alyftrek produced measurable pancreatic function recovery in a subset of pediatric patients during a recent study. The data were presented on October 9 and suggest a potential therapeutic benefit for a rare genetic disorder. The company highlighted the improvement as a significant milestone in its development program, indicating progress toward regulatory approval. The findings may enhance the drug’s commercial prospects and support future clinical trials. The announcement was received positively by the market, reflecting confidence in Vertex’s pipeline.
What did this article say?
Vertex Pharmaceuticals reported interim results from the ALYFTREK® open‑label extension study in children aged 2 to 5 with cystic fibrosis. The data showed recovery of exocrine pancreatic function in a subset of participants, enabling some to stop pancreatic enzyme replacement therapy. The findings were presented at the North American Cystic Fibrosis Conference and include additional clinical and real‑world evidence on CFTR modulators. This development supports the therapeutic benefit of ALYFTREK® in a younger population and may enhance its clinical positioning.
What did this article say?
Vertex Pharmaceuticals was reported to trade at a 29.0 times earnings multiple, higher than peers Regeneron and Incyte. The company’s operating margin of 37.9% surpassed Incyte’s 31.6%, indicating stronger profitability. However, Vertex’s sales growth lagged behind three of the other four comparable biotech firms, suggesting a slower expansion pace. The analysis weighed the premium investors pay for Vertex’s margin advantage against its modest growth trajectory.
What did this article say?
Vertex presented data from a study of its drug ALYFTREK in children aged 2 to 5 with cystic fibrosis, showing that some participants experienced recovery of pancreatic function. The presentation also included additional abstracts on clinical and real‑world evidence for CFTR modulators. The findings suggest a potential therapeutic benefit for early‑age patients and support ongoing development of the drug.
What did this article say?
Vertex and Moderna discontinued a clinical trial of an mRNA-based therapy for the subset of cystic fibrosis patients whose genetic mutations do not respond to existing treatments. The decision followed tolerability concerns that emerged during the study. The pause underscores ongoing challenges in expanding effective therapies to the remaining 10% of patients. The setback may delay Vertex’s broader pipeline progress and could influence investor perception of the company’s ability to deliver on its CF portfolio. The company has not announced an immediate replacement strategy for this patient group.
What did this article say?
Andrew Hill Investment Advisors released its third‑quarter 2026 investor letter, highlighting a bullish outlook for Vertex (VRTX). The fund noted that rising oil prices, higher interest rates, and inflationary pressures were offset by robust corporate earnings and continued AI investment, supporting the broader market. The letter emphasized VRTX’s positioning within the AI and biotech sectors, suggesting potential upside as demand for its technologies grows. While the letter did not disclose portfolio returns, it underscored confidence in VRTX’s long‑term growth prospects.
What did this article say?
RBC increased its price target for Vertex Pharmaceuticals to $576 from $570 while keeping an Outperform rating. The upgrade reflects confidence in the company’s pipeline and recent clinical developments. The adjustment signals a modest bullish outlook for the stock, suggesting potential upside for investors.
What did this article say?
RBC Capital analyst Brian Abrahams maintained an Outperform rating for Vertex Pharmaceuticals and increased the price target from $570 to $576. The upgrade reflects confidence in the company’s pipeline and recent clinical data. The new target suggests a potential upside for investors, reinforcing positive sentiment around the stock.
What did this article say?
Vertex Pharmaceuticals announced that it will report its third‑quarter 2026 financial results on November 2, 2026, after market close. The company scheduled a conference call and webcast at 4:30 p.m. ET, providing dial‑in numbers for U.S. and international participants. The announcement was purely informational, with no guidance or performance updates disclosed.

Technical Analysis

Real-time indicators across multiple timeframes

45
NEUTRAL
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $71.69B combined position · 15 adding, 10 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
Capital World Investors▲ Buy26,115,01410.03%$12.97B2026-08-12
BlackRock, Inc.▲ Buy24,109,3739.26%$11.98B2026-08-07
Vanguard Group Inc▼ Sell24,105,8239.26%$10.93B2026-01-29
Capital Research Global Investors▼ Sell19,490,6377.48%$9.68B2026-08-12
Invesco Ltd.▲ Buy8,043,0523.09%$4.00B2026-08-14
JPMorgan Chase & Co▼ Sell6,517,6002.50%$3.26B2026-08-12
Geode Capital Management, LLC▼ Sell6,017,8482.31%$2.98B2026-08-12
Loomis Sayles & Co L P▼ Sell3,920,9531.51%$1.95B2026-08-14
Wellington Management Group LLP▲ Buy3,247,6581.25%$1.61B2026-08-14
Morgan Stanley▲ Buy3,242,1391.25%$1.61B2026-08-13
Bank of America Corp▲ Buy3,039,1781.17%$1.51B2026-08-14
Norges Bank▼ Sell2,971,6811.14%$1.48B2026-08-12
AllianceBernstein L.P.▼ Sell3,019,3151.16%$1.35B2026-08-14
Northern Trust Corp▼ Sell2,486,4780.95%$1.24B2026-08-13
Goldman Sachs Group Inc▲ Buy2,481,7610.95%$1.23B2026-08-14
Janus Henderson Group plc▼ Sell2,131,5270.82%$951.79M2026-05-18
FMR LLC (Fidelity)▼ Sell1,457,1580.56%$723.81M2026-08-13
Wells Fargo & Company▲ Buy749,5280.29%$372.31M2026-08-14
Citigroup Inc▲ Buy706,9680.27%$351.17M2026-08-03
AQR Capital Management LLC▲ Buy616,1700.24%$305.00M2026-08-14
Neuberger Berman Group LLC▲ Buy559,4450.21%$277.89M2026-08-13
Marshall Wace, LLP▲ Buy543,8970.21%$270.17M2026-08-13
Citadel Advisors LLC▲ Buy510,4300.20%$253.55M2026-09-02
Millennium Management LLC▲ Buy468,4100.18%$232.67M2026-08-14
Adage Capital Partners GP, L.L.C.▲ Buy393,9640.15%$195.69M2026-08-14
Q2 2026 flow:5.37M sh bought ($2.67B)4.09M sh sold ($1.99B)net +1.28M sh (+$677.51M)
Congressional Trading Activity
17 disclosed trades · ~$209.5K est. traded value · 7 buys, 10 sells
MemberChamberStateTypeAmountTradedFiled
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-08-262026-09-05
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
David J. TaylorHouseOH02▼ Sell$1K - $15K2026-01-292026-02-02
David J. TaylorHouseOH02▲ Buy$1K - $15K2025-08-072025-09-02
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-06-112025-08-13
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-06-102025-08-13
Jefferson ShreveHouseIN06▼ Sell$15K - $50K2025-05-122025-06-22
Byron DonaldsHouseFL19▼ Sell$1K - $15K2025-03-202025-04-14
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-03-132025-04-11
Jefferson ShreveHouseIN06▲ Buy$15K - $50K2025-02-242025-03-09
Lisa McClainHouseMI09▲ Buy$1K - $15K2024-12-112025-08-13
Julia LetlowHouseLA05▲ Buy$1K - $15K2024-10-232026-01-13
Tommy TubervilleSenateAL▼ Sell$1K - $15K2024-05-032026-08-05
Tommy TubervilleSenateAL▲ Buy$1K - $15K2022-10-062022-11-10
John F. ReedSenateRI▼ Sell$1K - $15K2019-02-042019-03-01
John F. ReedSenateRI▼ Sell$1K - $15K2018-03-092018-03-12
John F. ReedSenateRI▼ Sell$1K - $15K2015-05-132015-05-27